EMA COVID-19 guidance: research and development

August 10, 2022

The European Medicines Agency (EMA) provides support to medicine developers researching and developing potential COVID-19 medicines. Dedicated guidance, rapid procedures and contact points are available.

EMA: COVID-19 guidance: research and development

Table of contents

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.

 

TAGS: EMA Europe News COVID-19 Regulatory Sciences

Related Articles

Computer generated image of COVID-19
EMA

June 15, 2022

EMA adopts first list of critical medicines for COVID-19

News On 7 June 2022, EMA's Medicines Shortages Steering Group (MSSG) adopted the list of critical medicines for the COVID-19 public health emergency. The medicines included in the list are authorised...

Continue reading the blog post
EMA

April 26, 2022

Facilitating global access to diabetes treatments for non-EU patients Share

April 22, 2022 EMA’s human medicines committee (CHMP) has given a recommendation for two diabetes mellitus treatments, Actrapid and Insulatard, for use outside the European Union (EU). EMA is...

Continue reading the blog post
COVID-19

April 1, 2020

COVID-19 Pandemic in the EU: Fraudulent Medicines, Test Kit Shortage, & EMA Guidance Regarding Ongoing Clinical Trials

As of March 27, 2020 Each health authority within the EU has information regarding COVID-19 (coronavirus) on its website. In this blog we will try to guide you through some of these recommendations...

Continue reading the blog post